Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer

被引:8
|
作者
Xue, Ting [1 ]
Xu, Peijia [1 ]
Padelford, Jonathan [2 ]
Xue, Xingkui [1 ]
Wu, Alyssa Y. [3 ]
Li, Yuancheng [2 ,3 ]
Wang, Liya [1 ]
机构
[1] Southern Med Univ, Affiliated Longhua Peoples Hosp, Sch Clin Med 3, Dept Radiol, Shenzhen 518109, Peoples R China
[2] LLC 5M Biomed, Atlanta, GA 30333 USA
[3] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA
关键词
Ultrafine iron oxide nanoparticle; Drug delivery; Pancreatic cancer; SN38; Targeting; FACTOR-I RECEPTOR; MRI CONTRAST ENHANCEMENT; MAGNETIC-RESONANCE; THERANOSTIC NANOPARTICLES; IRINOTECAN; SURVIVAL; GEMCITABINE; EXPRESSION; THERAPY; NANOMEDICINE;
D O I
10.1007/s10637-022-01231-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic cancer remains one of the most lethal cancers largely due to the inefficient delivery of therapeutics. Nanomaterials have been extensively investigated as drug delivery platforms, showing improved drug pharmacodynamics and pharmacokinetics. However, their applications in pancreatic cancer have not yet been successful due to limited tumor delivery caused by dense tumor stroma and distorted tumor vasculatures. Meanwhile, smaller-sized nanomaterials have shown improved tumor delivery and retention in various tumors, including pancreatic tumors, suggesting their potential in enhancing drug delivery. An ultrafine iron oxide nanoparticle (uIONP) was used to encapsulate 7-ethyl-10-hydroxyl camptothecin (SN38), the water-insoluble active metabolite of pancreatic cancer chemotherapy drug irinotecan. Insulin-like growth factor 1 (IGF-1) was conjugated to uIONP as a ligand for targeting pancreatic cancer cells overexpressing IGF-1 receptor (IGF1R). The SN38 loading and release profile were characterized. The pancreatic cancer cell targeting using IGF1-uIONP/SN38 and subsequently induced cell apoptosis were also investigated. IGF1-uIONP/SN38 demonstrated a stable drug loading in physiological pH with the loading efficiency of 68.2 +/- 3.5% (SN38/Fe, wt%) and < 7% release for 24 h. In tumor-interstitial- and lysosomal-mimicking pH (6.5 and 5.5), 52.2 and 91.3% of encapsulated SN38 were released over 24 h. The IGF1-uIONP/SN38 exhibited specific receptor-mediated cell targeting and cytotoxicity Ato MiaPaCa-2 and Panc02 pancreatic cancer cells with IC50 of 11.8 +/- 2.3 and 20.8 +/- 3.5 nM, respectively, but not to HEK293 human embryonic kidney cells. IGF1-uIONP significantly improved the targeted SN38 delivery to pancreatic cancer cells, holding the potential for in vivo theranostic applications.
引用
收藏
页码:546 / 555
页数:10
相关论文
共 50 条
  • [41] Hyaluronic Acid-decorated PLGA-PEG Nanoparticles for Targeted Delivery of SN-38 to Ovarian Cancer
    Vangara, Kiran Kumar
    Liu, Jingbo Louise
    Palakurthi, Srinath
    ANTICANCER RESEARCH, 2013, 33 (06) : 2425 - 2434
  • [42] A biocompatible superparamagnetic chitosan-based nanoplatform enabling targeted SN-38 delivery for colorectal cancer therapy
    Wu, Danjun
    Li, Yi
    Zhu, Lixi
    Zhang, Wangyang
    Xu, Shumin
    Yang, Yan
    Yan, Qinying
    Yang, Gensheng
    CARBOHYDRATE POLYMERS, 2021, 274
  • [43] Development of Chitosan-Coated Graphene Oxide and Iron Oxide Nanocomposites for Targeted Delivery of Camptothecin to Liver Cancer Cells
    Sukumar, Kalpana
    Bharathi, Muruganantham
    Hirad, Abdurahman Hajinur
    Alarfaj, Abdullah A.
    Hussein-Al-Ali, Samer Hasan
    Surya, Parthasarathy
    CHEMISTRY & BIODIVERSITY, 2025, 22 (02)
  • [44] CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates
    Govindan, Serengulam V.
    Cardillo, Thomas M.
    Moon, Sung-Ju
    Hansen, Hans J.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6052 - 6061
  • [45] Novel targeted aptamer-superparamagnetic iron oxide nanoparticle bioconjugates for combined prostate cancer imaging and therapy
    Wang, A. Z.
    Bagalkot, V.
    Gu, F.
    Alexis, F.
    Vasilliou, C.
    Cima, M.
    Jon, S.
    Farokhzad, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S110 - S111
  • [46] CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer
    Alibolandi, Mona
    Abnous, Khalil
    Anvari, Sajjad
    Mohammadi, Marzieh
    Ramezani, Mohammad
    Taghdisi, Seyed Mohammad
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 : S1159 - S1169
  • [47] Superparamagnetic iron oxide-reduced graphene oxide nanohybrid-a vehicle for targeted drug delivery and hyperthermia treatment of cancer
    Gupta, Jagriti
    Prakash, Anand
    Jaiswal, Manish K.
    Agarrwal, Atanuu
    Bahadur, D.
    JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2018, 448 : 332 - 338
  • [48] Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer
    Mahajan, Ujjwal M.
    Teller, Steffen
    Sendler, Matthias
    Palankar, Raghavendra
    van den Brandt, Cindy
    Schwaiger, Theresa
    Kuehn, Jens-Peter
    Ribback, Silvia
    Gloeckl, Gunnar
    Evert, Matthias
    Weitschies, Werner
    Hosten, Norbert
    Dombrowski, Frank
    Delcea, Mihaela
    Weiss, Frank-Ulrich
    Lerch, Markus M.
    Mayerle, Julia
    GUT, 2016, 65 (11) : 1838 - 1849
  • [49] Dextran-coated iron oxide nanoparticle for delivery of miR-29a to breast cancer cell line
    Yalcin, Serap
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2019, 24 (08) : 1032 - 1037
  • [50] Targeted therapy of human colonic, lung, and pancreatic cancer xenografts, growing in nude mice, with potent antibody conjugates of SN-38
    Govindan, Serengulam
    Cardillo, Thomas
    Moon, Sung-Ju
    Goldenberg, David
    CANCER RESEARCH, 2009, 69